Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS/MS

J Pharm Biomed Anal. 2023 Oct 25:235:115652. doi: 10.1016/j.jpba.2023.115652. Epub 2023 Aug 19.

Abstract

A fast and reliable QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method for pre-processing combined with Ultra - high performance liquid chromatography - tandem mass spectrometry (UHPLC-MS/MS) was established for the analysis of five mammalian rapamycin target protein (mTOR) inhibitors (vistusertib, AZD8055, pictilisib, everolimus, temsirolimus)in human plasma. Extraction was achieved by addition of acetonitrile to the sample followed by anhydrous magnesium sulfate and 30 mg C18 for salting out and purification, respectively. MTOR inhibitors were detected using selective response monitoring (SRM) under positive ion electrospray mode. Vistusertib, AZD8055 and pictilisib showed good linearity with a range of 1-80 ng/ml, Additionally, the concentration of everolimus and temsirolimus was 2.5-200 ng/ml and10-800 ng/ml, respectively. The linear correlation coefficient (R2) of each analysis was ≥ 0.9950. The limit of detection (LOD) and Limit of Quantitation (LOQ) were 0.015-0.75 ng/ml and 1-10 ng/ml, respectively. This method showed a high accuracy with high recovery rate and excellent stability. This method is fast, accurate and reliable, suitable for quantitative detection of mTOR inhibitors in human plasma.

Keywords: Human plasma; Mammalian target of rapamycin inhibitors; QuEChERS; UHPLC-MS/MS.

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular* / blood
  • Carcinoma, Hepatocellular* / drug therapy
  • Chromatography, High Pressure Liquid
  • Everolimus / blood
  • Everolimus / therapeutic use
  • Humans
  • Liver Neoplasms* / blood
  • Liver Neoplasms* / drug therapy
  • MTOR Inhibitors* / blood
  • MTOR Inhibitors* / therapeutic use
  • Tandem Mass Spectrometry

Substances

  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
  • Everolimus
  • MTOR Inhibitors
  • temsirolimus
  • vistusertib